During this month’s 36th Annual Virtual Congress of the European Association of Urology (EAU), 08-12 July, the ecancer online oncology platform hosted a virtual expert panel discussion on the role of genetic testing for prostate cancer in the clinic.
Chaired by Phil Cornford, the Royal Liverpool University Hospital (UK), panelists Joaquin Mateo, Principal Investigator of VHIO’s Prostate Cancer Translational Research Group, Alex Wyatt, Vancouver Prostate Centre (Canada), and Derya Tilki, Martini-Klinik Prostate Cancer, Hamburg (Germany), update on why genetic testing has become increasingly important towards more effectively combating prostate cancer.
VHIO’s Joaquin Mateo began by mentioning the PROfound and TRITON2 studies which led to the approval of PARPi olaparib in several countries across the globe, and rucaparib in the U.S., respectively. The experts then go on to cover a broad range of topics including current international guidelines on which patient populations should be tested and when, the potential benefits of early access to genetic information about castration-resistant prostate cancer (CRPC), as well as the common BRCA mutation alongside the differences between germline testing for hereditary mutations and tumor testing.
Conversation also focuses on next directions for optimal genetic counselling; particularly with increased testing anticipated in the future. The training of all specialists, as multidisciplinary teams, is proposed in order to provide patients with the necessary information to conduct testing. Reviewing the practical aspects, the speakers also discuss referrals for germline testing once a negative test for somatic mutations has been obtained, the relevance of a strong family history of disease, and the challenge of the potentially high failure rate of tumor testing due to sample viability.
To access this virtual expert discussion and discover more please click here, or visit https://ecancer.org/en/video.